8602399

pubmed:Citation

4

Chemoattractants expressed at bony sites and pelvic lymph nodes are thought to promote the preferential metastasis of human prostate tumor cells to these organs. Epidermal growth factor (EGF) is a potent chemoattractant for several human metastatic prostate tumor cell lines, including the TSU-pr1 cell line, and EGF has been localized to the stroma of both bony sites and pelvic lymph nodes in humans. Hence, we investigated whether the TSU-pr1 cell line expresses a functional EGF receptor (EGFR), which when antagonized reduces EGF-mediated chemomigration of this cell line. In this context, the EGFR immunoprecipitated from cell lysates of TSU-pr1 cells comigrated with the EGFR from A431 cells at a molecular weight of 170 kD. Addition of human EGF (hEGF) to the TSU-pr1 cells for 5 min stimulated the dose-dependent biphasic phosphorylation of the EGFR, with maximal stimulation of EGFR phosphorylation occurring at 2 ng/ml hEGF. In addition, treatment of hEGF-stimulated (2 ng/ml) TSU-pr1 cells with 0.5 microgram/ml anti-hEGF monoclonal antibody or 100 nM staurosporine inhibited EGFR phosphorylation. Conversely, as negative controls, treatment of hEGF-stimulated (2 ng/ml) TSU-pr1 cells with K252a or dimethyl sulfoxide (DMSO) vehicle did not inhibit EGFR phosphorylation. TSU-pr1 cells were stimulated to migration in 4 hr across Boyden chambers in response to 10 ng/ml hEGF. Treatment of the TSU-pr1 cells with anti-hEGFR monoclonal antibody inhibited in a dose-dependent manner the chemomigration of the TSU-pr1 cells across Boyden chambers. Similarly, treatment of the TSU-pr1 cells with staurosporine inhibited in a dose-dependent manner the chemomigration of the TSU-pr1 cells across Boyden chambers. These results demonstrate that antagonists of hEGF-mediated hEGFR phosphorylation also antagonize chemomigration of the TSU-pr1 cells across Boyden chambers, suggesting that antagonists of the EGFR in prostate cancer may be useful in the treatment of metastatic disease.

eng

IM

MEDLINE

0270-4137

Print

NLM

232-8

pubmed-meshheading:8602399-Alkaloids, pubmed-meshheading:8602399-Antibodies, Monoclonal, pubmed-meshheading:8602399-Carbazoles, pubmed-meshheading:8602399-Carcinogens, pubmed-meshheading:8602399-Carcinoma, pubmed-meshheading:8602399-Cell Movement, pubmed-meshheading:8602399-Dimethyl Sulfoxide, pubmed-meshheading:8602399-Enzyme Inhibitors, pubmed-meshheading:8602399-Epidermal Growth Factor, pubmed-meshheading:8602399-Humans, pubmed-meshheading:8602399-Immunoblotting, pubmed-meshheading:8602399-Indole Alkaloids, pubmed-meshheading:8602399-Male, pubmed-meshheading:8602399-Neoplasm Metastasis, pubmed-meshheading:8602399-Phosphorylation, pubmed-meshheading:8602399-Prostatic Neoplasms, pubmed-meshheading:8602399-Protein Kinase C, pubmed-meshheading:8602399-Receptor, Epidermal Growth Factor, pubmed-meshheading:8602399-Staurosporine, pubmed-meshheading:8602399-Tumor Cells, Cultured

Inhibition of chemomigration of a human prostatic carcinoma cell (TSU-pr1) line by inhibition of epidermal growth factor receptor function.

Journal Article, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't